Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 221

1.

Effects of intravenous administration of pirfenidone on horses with experimentally induced endotoxemia.

Poulin Braim AE, MacDonald MH, Bruss ML, Grattendick KJ, Giri SN, Margolin SB.

Am J Vet Res. 2009 Aug;70(8):1031-42. doi: 10.2460/ajvr.70.8.1031.

PMID:
19645586
4.

Pharmacokinetics and clinical effects of pirfenidone administered intravenously in horses.

Braim AE, Macdonald MH, Bruss ML, Stanley SD, Giri JK, Giri SN.

Am J Vet Res. 2008 Jul;69(7):952-60. doi: 10.2460/ajvr.69.7.952.

PMID:
18593250
6.

Effects of three anti-TNF-alpha drugs: etanercept, infliximab and pirfenidone on release of TNF-alpha in medium and TNF-alpha associated with the cell in vitro.

Grattendick KJ, Nakashima JM, Feng L, Giri SN, Margolin SB.

Int Immunopharmacol. 2008 May;8(5):679-87. doi: 10.1016/j.intimp.2008.01.013. Epub 2008 Feb 11.

PMID:
18387510
7.

Pharmacokinetics and metabolism of intravenous pirfenidone in sheep.

Bruss ML, Stanley SD, Margolin SB, Giri SN.

Biopharm Drug Dispos. 2008 Mar;29(2):119-26. doi: 10.1002/bdd.595.

PMID:
18176939
8.

Antirheumatic effect of pirfenidone in a double blind clinical pilot trial in humans.

Pesce E, Struma E, Giri SN, Margolin SB.

Res Commun Mol Pathol Pharmacol. 2004;115-116:39-48.

PMID:
17564304
9.

Influence of pirfenidone on airway hyperresponsiveness and inflammation in a Brown-Norway rat model of asthma.

Mansoor JK, Decile KC, Giri SN, Pinkerton KE, Walby WF, Bratt JM, Grewal H, Margolin SB, Schelegle ES.

Pulm Pharmacol Ther. 2007;20(6):660-8. Epub 2006 Sep 15.

PMID:
17049446
10.
11.

Modulation of articular chondrocyte activity by pirfenidone.

Benton HP, Esquivel AV, Rice AD, Giri SN.

Res Commun Mol Pathol Pharmacol. 2003;113-114:275-88.

PMID:
15686126
12.

Pharmacokinetics of orally administered pirfenidone in male and female beagles.

Bruss ML, Margolin SB, Giri SN.

J Vet Pharmacol Ther. 2004 Oct;27(5):361-7.

PMID:
15500575
13.

Effects of pirfenidone on the generation of reactive oxygen species in vitro.

Giri SN, Leonard S, Shi X, Margolin SB, Vallyathan V.

J Environ Pathol Toxicol Oncol. 1999;18(3):169-77.

PMID:
15281229
14.

Amelioration of doxorubicin-induced cardiac and renal toxicity by pirfenidone in rats.

Giri SN, Al-Bayati MA, Du X, Schelegle E, Mohr FC, Margolin SB.

Cancer Chemother Pharmacol. 2004 Feb;53(2):141-50. Epub 2003 Oct 15.

PMID:
14564477
15.
16.

Novel pharmacological approaches to manage interstitial lung fibrosis in the twenty-first century.

Giri SN.

Annu Rev Pharmacol Toxicol. 2003;43:73-95. Epub 2002 Jan 10. Review.

PMID:
12540741
17.

Abrogation of bleomycin-induced lung fibrosis by nitric oxide synthase inhibitor, aminoguanidine in mice.

Giri SN, Biring I, Nguyen T, Wang Q, Hyde DM.

Nitric Oxide. 2002 Sep;7(2):109-18.

PMID:
12223180
18.
19.

Effect of pirfenidone against vanadate-induced kidney fibrosis in rats.

Al-Bayati MA, Xie Y, Mohr FC, Margolin SB, Giri SN.

Biochem Pharmacol. 2002 Aug 1;64(3):517-25.

PMID:
12147304
20.

Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administration.

Giri SN, Wang Q, Xie Y, Lango J, Morin D, Margolin SB, Buckpitt AR.

Biopharm Drug Dispos. 2002 Jul;23(5):203-11.

PMID:
12116052

Supplemental Content

Support Center